One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

When Nicole Stovall stepped into her new role as Chief Diversity Officer at Merck, it wasn’t just another career milestone—it was the manifestation of years of purpose, persistence, and faith […] ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

Findings from a phase 3 study provided additional evidence that the first pneumococcal vaccine made specifically for adults ...